| Literature DB >> 27506452 |
Clementina Sitzia1, Andrea Farini1, Luciana Jardim2, Paola Razini1, Marzia Belicchi3, Letizia Cassinelli1, Chiara Villa1, Silvia Erratico4, Daniele Parolini1, Pamela Bella1, Joao Carlos da Silva Bizario5, Luis Garcia6, Marcelo Dias-Baruffi2, Mirella Meregalli3, Yvan Torrente7.
Abstract
Duchenne muscular dystrophy is the most common genetic muscular dystrophy. It is caused by mutations in the dystrophin gene, leading to absence of muscular dystrophin and to progressive degeneration of skeletal muscle. We have demonstrated that the exon skipping method safely and efficiently brings to the expression of a functional dystrophin in dystrophic CD133+ cells injected scid/mdx mice. Golden Retriever muscular dystrophic (GRMD) dogs represent the best preclinical model of Duchenne muscular dystrophy, mimicking the human pathology in genotypic and phenotypic aspects. Here, we assess the capacity of intra-arterial delivered autologous engineered canine CD133+ cells of restoring dystrophin expression in Golden Retriever muscular dystrophy. This is the first demonstration of five-year follow up study, showing initial clinical amelioration followed by stabilization in mild and severe affected Golden Retriever muscular dystrophy dogs. The occurrence of T-cell response in three Golden Retriever muscular dystrophy dogs, consistent with a memory response boosted by the exon skipped-dystrophin protein, suggests an adaptive immune response against dystrophin.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27506452 PMCID: PMC5154479 DOI: 10.1038/mt.2016.163
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454